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Abstract
Background: Since May 2014, all HIV positive children aged less than five years in Malawi are eligible for ART. For
children older than five years they are eligible if they are in WHO stage III/IV, if stage I/II, if their CD4<500 cells/mm
3.
Our goal was to compare the WHO clinical classification criteria (WHO stage+CD4/age) to CD4 count (CD4/age) on all
children. Prior to 2014, children aged 2–5 years in stage I and II were eligible for ART if their CD4 was<750 cells/mm
3.
We were interested in the increase in numbers of children in this age group who now meet the eligibility criteria and
their average CD4 count.
Methods: Data including age, stage and CD4 count were used. We examined the effect of using two different criteria;
WHO staging and checking CD4 count if stage I or II versus CD4 count on all, on the numbers of children eligibility for
ART in a cohort of 969 children aged 0 to 14 years in Blantyre, Malawi.
Results: Using WHO stage+CD4/age, 786 patients out of 969 would have been treated and 183 would not. Using
CD4/age, 745 patients out of 969 would have been treated and 224 would not. Within the 224 patients not treated by
CD4 classification, 41 were clinical stage III or IV. The most common staging condition in these 41 children was low
weight for age (i.e. underweight). 41% of children age2-5 years have a CD4 count >750.
Conclusion: Most children are correctly started on treatment using recent guidelines. 41% more children <5 years will
be started on ART.
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Background
There are 35 million people living with Human Immuno-
deficiency Virus (HIV) in the world, 25 million of these live
in Sub Saharan Africa (SSA) and about 10% are children
[1]. In the last decade the expansion of antiretroviral treat-
ment (ART) in resource limited settings has resulted in
eight million people receiving ART, and there were 39%
fewer deaths from HIV in 2013 in SSA than in 2005 [1].
However there are discrepancies between adults and chil-
dren in terms of treatment coverage. It is estimated that
28% of children aged less than 15 who required ART were
receiving it compared with 57% of adults [2]. To facilitate
the scale up of ART the World health Organization
(WHO) have published sequential ART guidelines for a
public health approach, the most recent being in 2013 [3].
ART eligibility in children relies on both clinical and im-
munological criteria with the aim to start those who require
ART with a minimum delay.
A meta-analysis of untreated HIV infected children in
resource poor settings, showed that CD4 count was the
strongest predictor of mortality followed by weight for
age [4]. It is desirable that all children are immunologic-
ally staged at diagnosis by measuring CD4+ T cells using
flow cytometry and have sequential tests every three to
six months, depending on their proximity to the thresh-
olds for ART initiation, to monitor disease progression
[5]. However, in many resource-limited settings, lack of
widely available diagnostic facilities to determine CD4
counts means that clinical staging is often the standard
of care [6]. The WHO HIVclinical staging classify subjects
into one of four categories, stage I to IV, progressing from
primary HIV infection to advanced HIV/AIDS. Initiation
of ART is recommended if the patient is clinically staged
as WHO clinical stage III or IV (WHO, 2007). A CD4
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or II and eligibility is determined if the CD4 is below an
age adjusted threshold, see Table 1 for the evolution of
recommendations over time [3,7,8].
Previous studies comparing clinical versus immunologic
staging in children have demonstrated that agreement
among eligibility criteria is poor. In a study in 2005 in
Kinshasa, using WHO 2004 guidelines, 32.6% of children
eligible by clinical criteria were not eligible according to
immunological criteria (CD4, CD4% or total lymphocyte
count) and 34.7% of children eligible on immunological
criteria were not eligible by clinical criteria [9]. A discrep-
ancy was also observed in Tanzania, by Johnson et al., who
reported that 22% of children who were staged as III/IV
did not have severe immunosuppression using WHO
2006 definitions and 52% of children who were staged as
stage I/II did have severe immunosuppression [10]. Chil-
dren who warrant treatment immunologically but who are
not eligible using clinical staging alone represent a failure
of the staging system. In view of reports of discrepancy,
we wished to compare our current practise of determining
eligibility by first staging our paediatric HIVantibody posi-
tive patients aged>5 years and only carrying out a CD4
test on those in stage I and II with carrying out a CD4 test
on all patients. We wished to evaluate if, by starting chil-
dren who are staged as III/IV automatically, we were start-
ing children earlier than they needed to be started, in a
setting where the durability of ART regimes has not been
fully determined and where we have no access to resist-
ance testing in the case of ART failure. We were also
interested in the specific categorizations that may in-
appropriately stage patients due to co-morbidities.
Guidelines on when to initiate ART in children in
Malawi have evolved over time in line with WHO guide-
lines. National guidelines were published in 2008 and
the pediatric component of these reflected the WHO 2006
guidelines [7]. These were updated in 2011 [11] and
these largely reflected the 2010 WHO guidelines [8]. The
Malawian 2014 guidelines [12], based on the WHO 2013
guidelines [3], recommend starting all children aged<
5 years on ARTand to use 500 cells/mm
3 as the threshold
for children older than five years. The trend has been to-
wards starting children on ART with higher CD4 counts
and towards using absolute numbers of CD4 cells rather
than percentage of total lymphocyte counts. Current UK
guidelines recommend that children aged<1 year are uni-
versally started on ART but children>1 year are started
on age specific CD4 thresholds [5]. The differences in the
recommendations reflect a programmatic approach in coun-
tries with limited access to regular laboratory monitoring.
We were also interested in the proportion of children who
are now eligible by virtue of their age alone and what the
average CD4 count of this group is. Our reason for interest
in the average CD4 is that hypersensitivity reactions to nevi-
rapine occur in children and are more common in patients
with a higher CD4 count [13] and nevirapine is part of our
first line regime.
Objectives
1. In view of the 2014 guidelines, our first objective
was to compare doing a clinical stage and carrying
out a CD4 test on stage I and II in children >5 years
versus the measurement of CD4 count on all
patients>5 years as a means to determine eligibility
for ART in children.
2. In view of the recent change of guidelines we wished
to look at the average CD4 of children aged 2–5 and
the proportion of children in this age group who will
automatically be started on ART but who would not
have been eligible prior to the WHO 2013/Malawian
2014 guidelines, i.e. the proportion of children aged




An observational cross sectional study on data routinely
collected on all children enrolled for pre ART care be-
tween July 2010 and December 2012 was analyzed.
Study setting
The nurse led pre ART clinic based at the Queen Elizabeth
Central Hospital in Blantyre, Malawi. Children are referred
to this clinic after their HIV diagnosis has been made from
inpatient services and from surrounding urban clinics. HIV
testing relies on two rapid tests for HIV-1 and HIV-2, De-
termine and Unigold (Determine; Abbott Laboratories,
Abbott Park, Illinois, USA and Uni-Gold; Trinity Biotech,
Bray, Ireland). The function of the clinic is to clinically
stage the patients and to perform CD4 count. In September
Table 1 Malawian age adjusted thresholds for ART eligibility in children who are in WHO stage I/II
WHO 2006/Malawian 2008 guidelines WHO 2010/Malawian 2011 guidelines WHO 2013/Malawi 2014
< 12 months ALL ALL ALL
12- 24 months <20% or <750 cells/mm
3 ALL ALL
24-35 months <20% or <750 cells/mm
3 <750 cells/mm
3 ALL
36-59 months <15% or <350 cells/mm
3 <750 cells/mm
3 ALL
>60 months <15% or <250 cells/mm <350 cells/mm
3 <500 cells/mm
3
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tient was staged as stage III or IV, they should not have a
CD4 measured but rather start ART immediately. However,
prior to this time a baseline CD4 was performed on all
patients, therefore we have clinical staging data and CD4
results on patients in all WHO clinical stages. There is no
user fee charged for this service and the clinic is open five
days each week, morning and afternoon.
Participants
All Children aged between 0–14 years of age, from July
2010 and December 2012, who were seen in the pre
ART at Queen Elizabeth Central Hospital were examined
and staged by WHO criteria. Limited data were recorded,
but those variables important for staging were noted.
WHO clinical staging is routinely performed. The condi-
tion which resulted in them being assigned to a given
stage was generally but not always recorded. CD4 counts
are performed by the central laboratory at QECH using
the Beckman Coulter Flow Care CD4 detection kit, and
recorded in the database.
Ethical approval
The study received ethical approval from the College of
Medicine ethics committee (COMREC).
Variables
Name, age and date of birth if known, weight, height, Z
score of weight for height, weight for age if <5 years,
clinical stage and CD4 count is collected for all patients
attending the pre ART clinic.
Statistical methods
Using the data from our pre ART clinic, we compared
two possible algorithms as a means to determine eligibil-
ity for ART, see Table 2. Our practice since May 2014 is
to start all children <5 years on ART, therefore this
group was treated the same in both algorithms.
1. Clinical staging on all children >5 years and carry
out a CD4 count on those in stage I and II, we call
this WHO stage+CD4/age algorithm or algorithm 1.
2. The measurement of CD4 count on all children>
5 years, we call this cd4/age algorithm or algorithm 2.
We compared using Fisher’s Exact.
Results
From our clinical database, we had 1591 patients who had
been encountered in clinic. Complete data for analysis was
available for 969 patients (age, WHO stage, CD4 count).
The distribution of patients by age bands which are
currently and recently used to determine treatment and
WHO clinical stage for the 969 patients in the study is
shown in Table 3. The median age in each stage and the
median and interquartile range of the CD4 counts in the
different WHO stages are summarized in Table 4, as ex-
pected the CD4 counts are higher in the lower stages.
Based on the WHO staging system (algorithm 1, WHO
stage+CD4/age), 786 patients out of 969 would have been
treated and 183 would not, Table 5. See Figure 1 for a
summary of the criteria for classifying patients by WHO
clinical stage. Based on the CD4 classification (algorithm
2, CD4/age, ignoring stage), 745 patients out of 969 would
have been treated and 224 would not. Within the 224 pa-
tients not treated by CD4/age classification, 41 were clin-
ical stage 3 or 4 and would have been treated using the
WHO+CD4/age criteria. CD4 counts for these 41 dis-
cordantly classified children are summarized in Table 6,
with a range of 667–1182 cells/mm
3. The most common
clinical feature was severe weight for age (21 children or
51%), tuberculosis (4 children or 10%), severe recurrent
bacterial infections (2 children or 5%) and unknown (6
children or 15%).
The average CD4 of children aged 2–5 years in each of
the clinical stages ranged between 667 in stage I to 410
in stage IV, Table 4. The cut off for this age group in the
WHO 2010/Malawian 2011 guidelines was 750 cells/mm
3.
There were 239 children in this age group, 97 children
had CD4 counts of >750 and 142 had CD4 counts <750,
Table 7. 41% of children in this age group would not have
been eligible for ART using the WHO 2010/Malawian




Using the WHO 2013 guidelines, more children in our
clinic qualify for ART treatment with the WHO+ CD4/
Table 2 CD4 counts on stage I and II versus CD4 counts
on all – a comparison of two algorithms
Algorithm I – WHO stage+CD4/age Algorithm II - CD4/age
Age<5 TREAT AGE<5 =TREAT
Age>5 Stage III or IV TREAT Age> 5
Stage I or II CD4<500= TREAT
CD4<500= TREAT CD4>500= Do not Treat
CD4>500= Do not Treat
Table 3 The distribution of patients by age category and
WHO clinical stage
WHO stage
Age 1 2 3 4 Total
< 2 59 12 43 11 125
2-5 yrs 133 29 71 6 239
> 5 326 143 126 10 605
Total 518 184 240 27 969
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patients were immunologically classified using CD4 counts
and age only, there would have been 41 fewer children eli-
gible for ART. These children were classified as Stage 3 or
4 but have CD4 counts> 500 cells/mm
3.T h em o s tc o m -
mon clinical feature which resulted in children who had
relatively high CD4 counts being classified as stage III/IV
was weight for age below the 3rd centile i.e. underweight.
Although all measures of anthropometric failure are more
prevalent in HIV positive children [14], low weight for age
is common in all Malawian children; 3- 5% of children
aged<5 years are severely underweight (weight for age
is <− 3SD) [15]. This may result in children being assigned
to WHO stages III/IV despite a relatively good immune
system. However the WHO 2013 guidelines results in the
majority of children who would benefit from ART receiv-
ing it and only a small proportion who are not immuno-
suppressed starting earlier than required, mostly due to
low weight for age.
Among the concerns of premature initiation of ART
include the risk for adverse effects as well as resistance
to first-line medications. However, this concern may be
unfounded. The risk of adverse effects of ARVs and re-
sistance to first-line medications was relatively low in a
retrospective cohort study of 1434 Malawian children.
Two percent of patients were on alternative first line treat-
ment due to adverse effects and 1.5% were on second-line
regimen due to ART failure after a median period on ART
of 1.8 years [16]. Five year survival of children on ART in
this setting is 96% [13].
Our findings contrast with findings in the adult litera-
ture where more adults qualify for ARV treatment with
CD4 classification than with the WHO classification. For
example, a study in Uganda demonstrated that 53% of
the patients in clinical stage I and II would have been
eligible for ART with using CD4 counts<250 cells/mm
3
and 49% using CD4 counts<350 cells/mm
3 [17]. A
study from Ghana found 29.5% of patients in stage I and
II to have CD4 counts<200 cells/mm
3 [18]. In Malawian
adults it was found that 25% of adults in stage I or II had
CD4 counts<250 cells/mm
3 and 46% had CD4 counts<
350 cells/mm
3 [19].
41% in the 2–5 year age group would not have been
eligible using the WHO 2010/Malawi 2011 guidelines
are eligible for ART using the WHO 2013/Malawian
2014 guidelines. There is little clinical evidence to sup-
port early initiation of ART in children aged 2–5 years
[20] and this is not current practice in the west [5],
although it may be justified on a programmatic basis
where there is limited access to CD4 counts [3].
Strengths and weakness of the study
This is a retrospective review of chart data which may
contain some errors.
Strengths and weakness compared to other studies
The sample sizes in this study are larger than other stud-
ies and use the most recent guidelines.
The discordant rate is much lower than that reported
by others and this is likely because we have used more
recent guidelines for the modelling of our data [9,10]. A
weakness compared to other studies is the fact that the
data was not collected prospectively [10].
Conclusions
Our current practise, based on the most recent guide-
lines, of clinically staging children, immediately starting
all children in stage III and IV and doing CD4 counts on
children who are found to be in stage I and II is likely to
result in the majority of children being correctly started
on treatment. Children who are staged as III or IV and
who have a high CD4 count are likely to have been
staged due to low weight for age. Treatment monitoring
needs to take this into account and viral loads in cases of
suspected failure should be done when a child on treat-
ment is falling across centiles rather than low weight for
age. The absence of a baseline CD4 in children who pre-
sented in stage III or IV means that immunological failure
may be difficult to diagnose and ideally virological failure
Table 4 The median [IQR] age (in months) and absolute CD4 count for the four WHO clinical stages
WHO stage
Age 1 2 3 4
Median age and IQR in months in each stage 72(41–108) 84(60–127) 63(27–111) 26(20–96)
< 2 599 [343–1003] 698 [272–1329] 546 [259–995] 389 [233–1037]
2-5 yrs 667 [393–945] 618 [457–884] 678 [359–929] 410 [335–592]
> 5 480 [324–724] 426 [255–597] 332 [108–634] 474 [199–973]
Table 5 The number of patients and median absolute
CD4 count with IQR are shown by each of the
classifications
CD4/Age (algorithm 2)
WHO stage, CD4 count
(algorithm 1)
No Treat Treat Total algorithm 1
No Treat 183 – 183
Treat 41 745 786
Total algorithm 2 224 745 969
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Malawian 2014 guidelines will result in an increase in chil-
dren aged 2–5 being started on ART and this will need to
be monitored in terms of adverse effects as a result of
starting children with high CD4s on ART and the known
Figure 1 A summary of the criteria for classifying patients by WHO clinical stage.
Table 6 The 41 discordant treatment patients by age





810 [667–1182] 973 [752–992]
Table 7 Children aged 2–5 eligible for ART on the WHO
2013/Malawian 2014 guidelines
Age <750 cells/mm >750 cells Total
2-5 years 142 97 239
% 59% 41% 100%
O’Hare et al. BMC Research Notes 2014, 7:666 Page 5 of 6
http://www.biomedcentral.com/1756-0500/7/666association between high CD4 and hypersensitivity when
using nevirapine.
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